Reed International PLC
Elsevier NV
2 March 2001
LETTER TO COMPANY ANNOUNCEMENTS OFFICE
We are writing to advise you that we have today received notification of the
following transactions in the ordinary shares of Elsevier NV:
1. A Prozes, a director of Reed International PLC, purchased 2,4335 American
Depositary Shares in Elsevier NV at US$27.8978 per ADS on 27 February 2001
and 2,100 American Depositary Shares in Elsevier NV at US$29.11 per ADS on
1 March 2001. Each Elsevier ADS represents two Elsevier ordinary shares.
As a consequence of the above transactions, Mr Prozes now holds an interest
in 23,160 Reed International ordinary shares and 16,320 Elsevier ordinary
shares.
2. D J Haank, a director of Reed International P.L.C. and Elsevier NV, exercised
an option over 35,000 Elsevier NV ordinary shares at an option price of
E11.93 per share on 1 March 2001.
Mr Haank sold 27,000 Elsevier NV ordinary shares on the same day at a price
of E15.35 per share, in order to meet the cost of exercising the above
option. He retained the remaining 8,000 Elsevier NV ordinary shares
As a consequence of the above transactions, Mr Haank now holds an interest
in 18,880 Elsevier ordinary shares.
FROM REED ELSEVIER
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.